Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2023 Sep 2.

Published in final edited form as: Vaccine. 2022 Aug 12;40(37):5413–5432. doi: 10.1016/j.vaccine.2022.06.065

Figure 4. — Effectiveness of HPV vaccination against CIN2+ by number of doses and duration of buffer period

1 dose vs 0 doses; 2 doses vs 0 doses; 3 doses vs 0 doses

Data included in this analysis were extracted from original published articles.

Gray area indicates the range of the CIs from the published studies for effectiveness of 3 doses using the longest buffer period.

CIN2+, cervical intraepithelial neoplasia grade 2, 3, or worse or adenocarcinoma in situ

^a Risk ratio includes different measures depending on study, including incidence rate ratio, prevalence ratio, risk ratio, odds ratio, or hazard ratio.

Inline graphic — Effectiveness of HPV vaccination against CIN2+ by number of doses and duration of buffer period

1 dose vs 0 doses; 2 doses vs 0 doses; 3 doses vs 0 doses

Data included in this analysis were extracted from original published articles.

Gray area indicates the range of the CIs from the published studies for effectiveness of 3 doses using the longest buffer period.

CIN2+, cervical intraepithelial neoplasia grade 2, 3, or worse or adenocarcinoma in situ

^a Risk ratio includes different measures depending on study, including incidence rate ratio, prevalence ratio, risk ratio, odds ratio, or hazard ratio.